Krystal Biotech disclosed early clinical signals for a mutation‑agnostic approach to cystic fibrosis, reporting data that the company says support a direct move into a pivotal trial. The firm announced clinical observations suggesting effective native protein delivery and functional benefit across mutation types. Company releases and clinical reports positioned the data as an early proof‑of‑concept that could broaden treatment options beyond mutation‑specific modulators. Krystal said it will pursue pivotal‑grade development paths and highlighted manufacturing and regulatory plans to support a registrational strategy.